Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?

Investors are weighing high-growth pharmaceutical specialists against established platform companies. Choosing between Axsome Therapeutics (NASDAQ:AXSM) and Moderna (NASDAQ:MRNA) requires understanding their distinct clinical focuses and varying financial trajectories over the next few years.

Axsome Therapeutics targets specialized psychiatric and neurologic markets with a portfolio of recently approved therapies. Moderna remains a leader in messenger RNA technology, attempting to pivot from its pandemic-era success into a multi-product vaccine and therapeutics powerhouse. This comparison examines their growth potential and risk profiles.

The case for Axsome Therapeutics

Axsome Therapeutics focuses on developing and commercializing therapies for central nervous system conditions. The company currently markets products for major depressive disorder, excessive daytime sleepiness, and acute migraines. Axsome is increasingly prominent among biotech stocks focused on specialized neurologic medicine. It maintains license agreements for intellectual property with various entities, including Pfizer Inc. (NYSE:PFE), and works with partners like Pharmanovia to expand its reach into international markets.

In the 12 months ended Sept. 30, 2026, revenue reached about $865.3 million. This represents significant growth of approximately 54% compared to the previous period. The company reported a net loss of around $157.3 million during this time. This resulted in a negative net margin of roughly 18.2%, although the company is narrowing its losses as commercial uptake of its newer products increases.

As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 2.7x. This metric compares total debt to shareholder equity, indicating that the company uses a high level of debt relative to its equity to finance operations. The current ratio, which measures the ability of a business to pay its short-term obligations, stands at approximately 1.6x. In the fiscal year ended Dec. 31, 2025, free cash flow was nearly negative $93.9 million.

The case for Moderna

Moderna utilizes its proprietary messenger RNA platform to create a diverse pipeline of vaccines and therapeutics. The company has moved beyond its initial success in COVID-19 to launch products for respiratory syncytial virus and is advancing candidates in oncology. It maintains strategic collaborations with Merck & Co. (NYSE:MRK) for personalized cancer treatments and has licensing agreements with Arbutus Biopharma (NASDAQ:ABUS). These partnerships allow the company to leverage its platform across dozens of ongoing clinical trials.

In the 12 months ended Sept. 30, 2026, revenue was about $2.5 billion. This reflects a growth rate of approximately 13.7% over the prior twelve-month period. Despite this revenue, the company recorded a net loss of around $2.8 billion. This led to a negative net margin of roughly 110.5%, as the firm continues to invest heavily in research and development to expand its product pipeline for the coming years.

As of its December 2025 balance sheet, the debt-to-equity ratio was approximately 0.2x. This indicates a low level of debt relative to shareholder equity, providing the company with a relatively clean capital structure. The current ratio stands at a robust 3.3x, suggesting strong short-term liquidity. In the fiscal year ended Dec. 31, 2025, free cash flow was approximately negative $2.1 billion as the company funded its extensive clinical development programs.

Risk profile comparison

Axsome Therapeutics faces substantial competitive threats from major pharmaceutical companies and generic manufacturers, including Teva Pharmaceuticals Ltd (NYSE:TEVA) and Apotex Health. The business relies heavily on third-party manufacturers and service providers for its core operations, which can create supply chain vulnerabilities. Additionally, the company carries significant indebtedness under a loan facility with Blackstone. This debt includes restrictive covenants that could limit financial flexibility if revenue growth does not meet expectations.

Moderna faces intense competition from well-established giants such as Pfizer, Sanofi (NASDAQ:SNY), and GSK (NYSE:GSK). The company also deals with significant regulatory uncertainty and evolving recommendations regarding its vaccine franchise, which can lead to unpredictable demand. Furthermore, the business depends on complex, single-source manufacturing processes and cold-chain logistics. Ongoing intellectual property litigation related to messenger RNA technology also presents a potential risk to its long-term patent protections.

Valuation comparison

Axsome Therapeutics appears to be the more conservatively valued option as it trades at a significantly lower multiple of both its future earnings estimates and its sales over the past twelve months.

Valuation metrics include those sourced from Financial Modeling Prep (FMP) and may differ from those of other data providers.

Which stock would I buy for 2027?

Axsome right now is a three-drug business: Auvelity, Sunosi, and Symbravo. But there is a promise of a broadening of the offerings in the future. Axsome has trials ongoing in smoking cessation, ADHD, binge eating disorder, major depressive disorder with symptoms of excessive daytime sleepiness or excessive sleepiness, fibromyalgia, and shift work disorder. It also has programs that are in the works for schizophrenia, epilepsy, and Tourette's.

Still, the near term is driven by its three offerings. Auvelity generated $208 million in sales in the third quarter of 2026, up 53% year-over-year, with management seeing peak sales eventually of $8 billion. Similarly, Sunosi brought in $46 million in quarterly sales, with management saying its peak could be $300 million to $500 million one day. Axsome pulled in just about $260 million in sales in the third quarter of 2026, with a much narrower net loss of $12.9 million.

The COVID-19 vaccine developed by Moderna was a proof of concept of the power of mRNA research to quickly produce new treatments. Unfortunately for Moderna, the decline in people getting the COVID vaccine, along with numerous competitors with their own vaccines, has hammered the company's revenue in recent years. A more recent RSV vaccine reached the market after competing vaccines, resulting in less-than-robust adoption.

Still, Moderna has some 25 mRNA development candidates across 35 development programs in its portfolio. Seeing those come to market and make a meaningful impact on the business will take some time, however. Next year is likely when one or more of the products will get to market, and it is probably not until 2028 that significant revenue will hit the top line. In fiscal 2026, Moderna is expected to post modest sales growth of about 23% to around $2.4 billion in revenue, with a net loss of around $2.9 billion, slightly larger than 2025.

Moderna is a potentially revolutionary business based on its advances in mRNA. But its shares come at an exceptional premium today, making Axsome the better buy while still buying strong revenue growth for 2027.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Axsome Therapeutics, Merck, Moderna, and Pfizer. The Motley Fool has a disclosure policy.